#1 Clinical Trials Search in Europe

Study on Atezolizumab, Amivantamab, and Futibatinib for Patients with Advanced Solid Tumors

2 1 1 1

What is this study about?

This clinical trial is focused on studying advanced solid tumors, which are types of cancer that have spread and are difficult to remove with surgery. The study aims to evaluate the effectiveness of specific treatments for these cancers. The treatments being tested include atezolizumab, known by its code name RO5541267, amivantamab, and futibatinib. These medications are designed to target specific characteristics of the cancer cells.

The purpose of the study is to assess how well these treatments work in small groups of patients who have been selected based on the specific molecular features of their tumors. Participants will receive one of the treatments, which may be given as a solution for infusion, meaning it is administered directly into the bloodstream through a vein, or as a tablet taken by mouth. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatments.

The study will be conducted over a period of time, during which participants will be monitored for their response to the treatment. This includes checking for any changes in the size or spread of the tumors and observing any side effects. The goal is to find out if these treatments can help control the cancer and improve the quality of life for patients with advanced solid tumors.

1 joining the study

Upon joining the study, eligibility is confirmed based on specific criteria, including having an advanced solid tumor that is metastatic or cannot be surgically removed.

Consent is required to participate, and understanding of the study details is necessary.

2 treatment assignment

Participants are assigned to a treatment based on the molecular profile of their tumor.

The study involves three medications: atezolizumab, amivantamab, and futibatinib.

3 medication administration

Atezolizumab is administered as a solution for infusion through a vein (intravenous use).

Amivantamab is also given as a solution for infusion through a vein.

Futibatinib is taken orally in the form of film-coated tablets.

4 treatment duration and frequency

The duration and frequency of each medication depend on the specific module of the study and the participant’s response to treatment.

Regular monitoring and assessments are conducted to evaluate the effectiveness of the treatment.

5 monitoring and assessments

Participants undergo regular health assessments to monitor the response to the treatment.

These assessments include imaging tests and laboratory evaluations to track tumor response and overall health.

6 end of study participation

The study is estimated to conclude by July 19, 2026.

Participants may continue to receive treatment until the study ends or until it is determined that the treatment is no longer beneficial.

Who Can Join the Study?

  • Participants must have a confirmed advanced solid tumor that is either spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable).
  • Participants must have tried standard treatments, but these treatments have not worked, or no other approved treatments are available.
  • Participants must be able to understand and agree to sign a consent form to join the study.
  • Participants must have proper kidney and liver function. This means certain blood tests must be within specific limits.
  • Participants taking blood thinners (like heparin or warfarin) should be on a stable dose.
  • Women who can have children must agree to use birth control or not have heterosexual intercourse during the study.
  • Men must agree to use birth control or not have heterosexual intercourse and not donate sperm during the study.
  • Participants must have a good general health status, which is measured by a scale called ECOG performance status. They should score 0 or 1, indicating they are fully active or have some restrictions but can still do light work.
  • Participants must be 18 years old or older.
  • Participants must have a tumor that can be measured using specific guidelines called RECIST 1.1. For prostate cancer, other specific guidelines apply.
  • Participants must provide enough tumor tissue for analysis. This can be from stored samples or a new biopsy if needed.
  • Participants must have enough healthy blood cells, including white blood cells and platelets, as shown by blood tests.
  • Participants must be willing to take part in a study that matches treatment to the specific characteristics of their tumor.

Who Cannot Join the Study?

  • Patients who do not have an advanced solid tumor cannot participate. An advanced solid tumor is a type of cancer that forms a mass or lump in the body and has progressed to a more severe stage.
  • Patients who are not within the specified age range cannot participate. The age range includes adults and older adults.
  • Patients who are not part of the specified clinical trial groups cannot participate. Clinical trial groups are categories of patients based on certain characteristics needed for the study.
  • Patients who are not willing to follow the study procedures and requirements cannot participate.
  • Patients who are part of a vulnerable population, such as those who may not be able to give informed consent, cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Institut Gustave Roussy Villejuif France
Technische Universitaet Dresden Dresden Germany
Universitaetsklinikum Heidelberg AöR Heidelberg Germany

Other Sites

Site Name City Country Status
Netherlands Cancer Institute Amsterdam The Netherlands
Karolinska University Hospital Solna Sweden
Fondazione I.R.C.C.S. Istituto Neurologico Besta Milan Italy
Hcpfhpqs Vpxv djfralfh Barcelona Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Recruiting
20.12.2018
Germany Germany
Recruiting
20.12.2018
Italy Italy
Recruiting
20.12.2018
Spain Spain
Recruiting
20.12.2018
Sweden Sweden
Recruiting
20.12.2018
The Netherlands The Netherlands
Recruiting
20.12.2018

Trial locations

Investigated drugs:

Targeted Agents are specialized treatments used in this study to address specific characteristics of advanced solid tumors. These agents are designed to target and interfere with molecules that are involved in the growth, progression, and spread of cancer. By focusing on these specific targets, the therapy aims to reduce the tumor size or slow its growth, providing a more personalized treatment approach for patients with certain molecular profiles.

Prostate Cancer – Prostate cancer is a disease where cells in the prostate gland grow uncontrollably. It often progresses slowly and may not show symptoms in the early stages. As it advances, it can cause urinary problems, pelvic discomfort, and bone pain. The disease can spread to nearby tissues or other parts of the body, such as bones and lymph nodes. The progression can vary greatly among individuals, with some experiencing rapid growth and others having a more indolent course.

Trial ID:
2024-514238-19-00
Protocol code:
VHIO17002
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • A Phase I/II Study of GVV858 Alone or in Drug Combination for Patients with Advanced Hormone Receptor‑Positive, HER2‑Negative Breast Cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany Italy Spain

  • A study of PM54 and pembrolizumab in adults with advanced cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain